Clinical traction Centese has ongoing and historical clinical studies and peer‑reviewed publications around its Thoraguard digital drainage system, including collaborations with Stanford University Medical Center. This indicates potential for hospital-based sales approaches and those seeking evidence of clinical efficacy.

Strategic leadership Recent board expansion with Timothy Still joining the Board of Directors signals a push for governance and strategic growth, suggesting opportunities for high‑level partnerships, larger hospital networks, and potential access to decision makers.

Regulatory credibility Multiple peer‑reviewed studies and public announcements demonstrate credibility in the cardiovascular and thoracic surgical space, which can facilitate outreach to procurement teams prioritizing evidence‑based, proven medical devices.

Global visibility Public filings and press coverage across reputable outlets indicate growing market presence; leverage external validation to approach multi‑center hospital systems and regional distributors seeking validated innovations.

Growth potential With revenue in the low single digits to mid range and a funding level around fifteen million, Centese appears positioned for expansion into additional markets and clinical settings, presenting opportunities for channel partnerships, clinical program pilots, and hospital adoption drives.